Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,659
archived clinical trials in
Metabolic

Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Evans Army Hospital
1163
mi
from 43215
Fort Carson, CO
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Evans Army Hospital
1163
mi
from 43215
Fort Carson, CO
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Children´s Hospital Boston
643
mi
from 43215
Boston, MA
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Children´s Hospital Boston
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Rainbow Babies & Children´s Hospital
129
mi
from 43215
Cleveland, OH
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Rainbow Babies & Children´s Hospital
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
The Children´s Medical Center of Dayton
61
mi
from 43215
Dayton, OH
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
The Children´s Medical Center of Dayton
61
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Rhode Island Hospital
619
mi
from 43215
Providence, RI
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Rhode Island Hospital
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Cook Children´s Medical Center
937
mi
from 43215
Fort Worth, TX
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Cook Children´s Medical Center
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
University of Texas Medical Branch
992
mi
from 43215
Galveston, TX
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
University of Texas Medical Branch
992
mi
from 43215
Galveston, TX
Click here to add this to my saved trials
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated:  10/19/2017
Texas Children´s Hospital
995
mi
from 43215
Houston, TX
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Status: Enrolling
Updated: 10/19/2017
Texas Children´s Hospital
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
481
mi
from 43215
New York, NY
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
549
mi
from 43215
Stony Brook, NY
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
549
mi
from 43215
Stony Brook, NY
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
327
mi
from 43215
Washington, D.C.,
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
327
mi
from 43215
Washington, D.C.,
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Research Site
484
mi
from 43215
The Bronx, NY
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Research Site
484
mi
from 43215
The Bronx, NY
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
Click here to add this to my saved trials
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated:  10/27/2017
4021
mi
from 43215
Gent,
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)
Status: Enrolling
Updated: 10/27/2017
4021
mi
from 43215
Gent,
Click here to add this to my saved trials
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
Status: Enrolling
Updated:  10/30/2017
University of Arizona Collaboratory for Metabolic Disease Prevention and Treatment
1641
mi
from 43215
Tucson, AZ
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
Status: Enrolling
Updated: 10/30/2017
University of Arizona Collaboratory for Metabolic Disease Prevention and Treatment
1641
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Evaluation of Neuroinflammation in Children With Infantile Spasms
Neuroinflammation in Children With Infantile Spasms Measured With 11C-PK11195 Positron Emission Tomography: Response to ACTH
Status: Enrolling
Updated:  11/3/2017
Children's Hospital of Michigan
164
mi
from 43215
Detroit, MI
Evaluation of Neuroinflammation in Children With Infantile Spasms
Neuroinflammation in Children With Infantile Spasms Measured With 11C-PK11195 Positron Emission Tomography: Response to ACTH
Status: Enrolling
Updated: 11/3/2017
Children's Hospital of Michigan
164
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Status: Enrolling
Updated:  11/8/2017
NYU Langone Medical Center
478
mi
from 43215
New York, NY
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Status: Enrolling
Updated: 11/8/2017
NYU Langone Medical Center
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
Stem Cell Transplant for Inborn Errors of Metabolism
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Stem Cell Transplant for Inborn Errors of Metabolism
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Stem Cell Transplantation for Hurler
Hematopoietic Stem Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Stem Cell Transplantation for Hurler
Hematopoietic Stem Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  12/3/2017
University of Minnesota - Fairview
624
mi
from 43215
Minneapolis, MN
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 12/3/2017
University of Minnesota - Fairview
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
Comparative Efficacy of Phenylbutyrate vs. Benzoate in Urea Cycle Disorders
Status: Enrolling
Updated:  12/9/2017
Children's Nutrition Research Center, Baylor College of Medicine
995
mi
from 43215
Houston, TX
Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
Comparative Efficacy of Phenylbutyrate vs. Benzoate in Urea Cycle Disorders
Status: Enrolling
Updated: 12/9/2017
Children's Nutrition Research Center, Baylor College of Medicine
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
New York Medical College
491
mi
from 43215
Valhalla, NY
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
New York Medical College
491
mi
from 43215
Valhalla, NY
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
University of Utah
1511
mi
from 43215
Salt Lake City, UT
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
University of Utah
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
Childrens Hospital Colorado
1162
mi
from 43215
Denver, CO
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
Childrens Hospital Colorado
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders
Status: Enrolling
Updated:  1/9/2018
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders
Status: Enrolling
Updated: 1/9/2018
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Department of Human Genetics, Emory University School of Medicine
432
mi
from 43215
Atlanta, GA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Department of Human Genetics, Emory University School of Medicine
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
University of Iowa Health Clinics
460
mi
from 43215
Iowa City, IA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
University of Iowa Health Clinics
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Johns Hopkins University School of Medicine
345
mi
from 43215
Baltimore, MD
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Johns Hopkins University School of Medicine
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Research Baylor Institute of Metabolic Disease
910
mi
from 43215
Dallas, TX
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Research Baylor Institute of Metabolic Disease
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
O&O Alpan
315
mi
from 43215
Fairfax, VA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
O&O Alpan
315
mi
from 43215
Fairfax, VA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
The Royal Melbourne Hospital
9882
mi
from 43215
Parkville,
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
The Royal Melbourne Hospital
9882
mi
from 43215
Parkville,
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
1959
mi
from 43215
Orange, CA
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
643
mi
from 43215
Boston, MA
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
609
mi
from 43215
Lebanon, NH
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
609
mi
from 43215
Lebanon, NH
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
6
mi
from 43215
Columbus, OH
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
6
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
64
mi
from 43215
Dayton, OH
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
64
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated:  1/16/2018
Clinical Research Facility
991
mi
from 43215
Houston, TX
Ceprotin Treatment Registry
Ceprotin Treatment Registry
Status: Enrolling
Updated: 1/16/2018
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials